Moshe Ornstein, MD

Experts discuss how treatment sequencing in advanced renal cell carcinoma (RCC) may evolve with the emergence of novel combinations and highlight emerging data from ASCO GU 2025 likely to impact clinical practice.

Experts discuss the role of belzutifan and tivozanib in the treatment paradigm for advanced renal cell carcinoma (RCC), including key findings from the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.

Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.

Experts discuss emerging patterns of progression with current frontline regimens for advanced renal cell carcinoma (RCC), differences between immunotherapy (IO)/IO and IO/tyrosine kinase inhibitor (TKI) combinations, and how these progression patterns impact prognosis and subsequent therapy selection, considering whether the patient received IO/IO or IO/TKI in the first line and the clinical factors influencing later-line treatment decisions.

Experts discuss regimens with the most favorable toxicity profiles and how they personalize treatment to minimize patient burden, while also exploring preferred strategies for patients who have completed pembrolizumab in the adjuvant setting and how the timing of recurrence relative to adjuvant therapy completion influences treatment selection.

Experts discuss key factors influencing the decision between immunotherapy (IO)/IO and various IO/tyrosine kinase inhibitor (TKI) combinations in advanced renal cell carcinoma (RCC) treatment, including patient characteristics, risk stratification, PD-L1 status, and other clinical features, while also exploring the patient experience with IO-TKI regimens, strategies for managing adverse effects, and the approach to hepatotoxicity management.

Experts discuss the key findings from the final follow-up results of the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib in advanced renal cell carcinoma (RCC) and share perspectives on the clinical implications of these updated data, along with insights from other studies of note, including LITESPARK-003 (belzutifan plus cabozantinib) and LITESPARK-024 (belzutifan plus palbociclib).

Experts discuss how emerging novel doublet regimens in the frontline setting for advanced renal cell carcinoma may address current unmet needs, highlighting specific biomarkers, patient populations, and clinical scenarios where these combinations could offer distinct advantages over existing standards like immunotherapy (IO)/IO or established IO/tyrosine kinase inhibitor (TKI) combinations.

Experts discuss the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plus ipilimumab for first-line treatment of advanced renal cell carcinoma (RCC), and how these mature overall survival (OS) data influence the view of nivolumab plus ipilimumab as a frontline option, alongside insights from efficacy, safety, post hoc subgroup analyses (Albiges et al, Eur Urol, 2022), and health-related quality of life (HRQOL) data (Cella et al, J Clin Oncol, 2022).

Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit.

Martin H. Voss, MD, presents data supporting the use of various combination regimens in the frontline treatment of renal cell carcinoma (RCC), focusing on the pivotal trials such as CheckMate 214, KEYNOTE 426, and the CLEAR trial, emphasizing their respective efficacy, safety, and overall impact on the current treatment landscape for RCC patients.

Moshe Ornstein, MD, presents a detailed clinical case study of a 61-year-old male patient diagnosed with renal cell carcinoma.

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.

Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.

Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.

Martin H. Voss, MD, and Moshe Ornstein, MD, engage in a professional discourse concerning the current treatment standards and the evolving therapeutic landscape for non-clear cell renal cell carcinoma (RCC).

The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Moshe Ornstein, MD, MA, discusses unmet needs in metastatic renal cell carcinoma.